OTCMKTS:INCPF InnoCare Pharma (INCPF) Stock Price, News & Analysis $1.55 0.00 (0.00%) As of 06/26/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartHeadlinesBuy This Stock About InnoCare Pharma Stock (OTCMKTS:INCPF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get InnoCare Pharma alerts:Sign Up Key Stats Today's Range$1.55▼$1.5550-Day Range$1.55▼$1.5552-Week Range$1.55▼$2.31VolumeN/AAverage Volume550 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingBuy Company Overview InnoCare Pharma Ltd is a China-based, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule targeted therapies for oncology. Headquartered in Shenzhen, Guangdong Province, the company leverages structure-based drug design and comprehensive preclinical screening to advance drug candidates that address high-unmet-need cancers. The company’s development pipeline comprises multiple small-molecule inhibitors in various stages of preclinical and early clinical evaluation. InnoCare has prioritized programs that target solid tumors, including gastrointestinal and other hard-to-treat malignancies. Its research platform integrates in vitro and in vivo models to optimize lead compounds for potency, selectivity and safety. Founded and headquartered in Shenzhen, InnoCare Pharma draws on a multidisciplinary team of medicinal chemists, biologists and clinical development experts. While its initial focus is on serving patients in Greater China, the company is exploring global partnerships and regulatory pathways to extend the reach of its oncology portfolio beyond domestic markets.AI Generated. May Contain Errors. Read More Receive INCPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InnoCare Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INCPF Stock News HeadlinesInnoCare Shareholders Approve All Resolutions at 2026 AGMJune 16, 2026 | tipranks.comPhase IIb Study Results of InnoCare's Orelabrutinib in Patients with SLE Presented at 2026 EULARJune 4, 2026 | globenewswire.comTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.June 27 at 1:00 AM | Reagan Gold Group (Ad)ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML ReleasedJune 2, 2026 | globenewswire.comInnoCare Announces the Acceptance of New Drug Application for Orelabrutinib in Primary Immune Thrombocytopenia in ChinaMay 28, 2026 | globenewswire.comInnoCare Announces Approval of Orelabrutinib in AustraliaMay 27, 2026 | globenewswire.com2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax ReleasedMay 22, 2026 | globenewswire.comInnoCare Announce First Subject Dosed in Phase 1 Clinical Trial of ICP-054, a Novel Potentially Best-in-Class Oral IL-17AA/AF InhibitorMay 13, 2026 | globenewswire.comSee More Headlines INCPF Stock Analysis - Frequently Asked Questions How have INCPF shares performed this year? InnoCare Pharma's stock was trading at $2.05 on January 1st, 2026. Since then, INCPF stock has decreased by 24.4% and is now trading at $1.55. How do I buy shares of InnoCare Pharma? Shares of INCPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today6/27/2026Next Earnings (Estimated)8/25/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:INCPF CIKN/A Webwww.innocarepharma.com Phone861066609999FaxN/AEmployees1,089Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free Report This page (OTCMKTS:INCPF) was last updated on 6/27/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredSpaceX is offering you shares. Don't take them.SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. At a $...Behind the Markets | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InnoCare Pharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share InnoCare Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.